

## Supplementary

### Tables

**Table S1. Comparison of clinicopathological characteristics between LNR subgroups among pN1a-b and pN2 stages**

Variable	pN1a-b <i>p</i> for LNR ≤0.10 vs >10	pN2 <i>p</i> for LNR ≤0.25 vs >0.25
Age	0.351	0.482
Gender	0.857	0.657
Diabetes	0.897	0.944
Hypertension	0.679	0.815
CAD	0.812	0.409
Primary tumor location	0.155	0.672
Urgent surgery	0.821	0.963
pT stage	0.112	0.748
Tumor grade	<b>0.033</b>	0.848
Mucinous component	0.885	0.210
LVI	0.778	0.195
PNI	0.514	0.114
Budding	0.755	0.687
MSI-H	0.604	0.660
RAS mutation	0.126	0.522
RAF mutation	NC	0.657
ABO groups	0.642	0.915
Rh	0.876	0.251
Adjuvant chemotherapy type	0.618	0.208

Abbreviations: CAD: coronary artery disease, LVI: lymphovascular invasion, PNI: perineural invasion, MSI-H: microsatellite instability-high, NC: Not calculated

**Table S2. Univariable Cox regression analysis for RFS**

Variable	HR (95% CI)	P
<b>Age (Continuous variable)</b>	0.97 (0.94-1.00)	0.127
<b>Gender, (Male vs. female)</b>	0.82 (0.34-2.00)	0.674
<b>Diabetes (Present vs absent)</b>	0.87 (0.25-2.98)	0.829
<b>Hypertension, (Present vs absent)</b>	1.88 (0.68-5.19)	0.221
<b>CAD, n (%)</b>	0.94 (0.21-4.08)	0.939
<b>Tumor location (Left vs right)</b>	0.79 (0.50-1.23)	0.300
<b>Urgent surgery (Obstruction vs. no)</b>	1.82 (0.77-4.32)	0.169
<b>T stage (T4 vs T3)</b>	1.77 (0.73-4.29)	0.203
<b>Lymph node examined (Continuous variable)</b>	0.99 (0.96-1.03)	0.927
<b>Lymph node involved (Continuous variable)</b>	1.21 (1.11-1.33)	<b>0.000</b>
<b>LNR (Continuous variable)</b>	111.16 (17.35-711.89)	<b>0.000</b>
<b>N stage (pN2 vs pN1a-n)</b>	3.43 (1.42-8.32)	<b>0.006</b>
<b>Tumor grade (3 vs 2)</b>	0.71 (0.08-5.73)	0.535
<b>Mucinous component (Present vs absent)</b>	3.11 (1.29-7.51)	<b>0.012</b>
<b>LVI (Present vs absent)</b>	1.84 (0.73-4.62)	0.192
<b>PNI (Present vs absent)</b>	1.41 (0.58-3.42)	0.439
<b>Budding (Present vs absent)</b>	1.07 (0.41-2.79)	0.888
<b>MSI-H (Yes vs No)</b>	2.60 (0.75-9.03)	0.130
<b>RAS (Mutant vs WT)</b>	4.84 (1.35-17.25)	<b>0.015</b>
<b>ABO group</b>		
<b>A vs AB</b>	0.63 (0.14-2.90)	0.575
<b>B vs AB</b>	0.19 (0.01-2.13)	0.181
<b>O vs AB</b>	0.28 (0.04-2.05)	0.215
<b>Rh (Negative vs positive)</b>	0.51 (0.06-3.84)	0.515
<b>Perioperative treatment (Yes vs No)</b>	0.04 (0.00-55.20)	0.38
<b>Adjuvant chemotherapy (XELOX vs FOLFOX)</b>	1.42 (0.75-2.68)	0.276
<b>Adjuvant chemotherapy cycle (Continuous variable)</b>	0.92 (0.78-1.08)	0.337

Abbreviations: CAD: coronary artery disease, LNR: lymph node ratio, LVI: lymphovascular invasion, PNI: perineural invasion, WT: wild type, FOLFOX: Fluorouracil, leucovorin, and oxaliplatin, MSI-H: microsatellite instability-high, UK: unknown, XELOX: Capecitabine and oxaliplatin.